Literature DB >> 28923906

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.

Kristina Striepe1, Agnes Jumar1, Christian Ott1, Marina V Karg1, Markus P Schneider1, Dennis Kannenkeril1, Roland E Schmieder2.   

Abstract

Entities:  

Keywords:  SGLT-2 inhibitor; central systolic pressure; empagliflozin; pulse wave analysis; type 2 diabetes mellitus

Mesh：

Substances：

Year:  2017        PMID： 28923906     DOI： 10.1161/CIRCULATIONAHA.117.029529

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  45 in total

Review 1.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

Review 2.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 3.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield
Journal:  Eur J Clin Pharmacol       Date:  2019-08-03       Impact factor: 2.953

4.  Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.

Authors:  Hafiz Imran; William Nester; Islam Y Elgendy; Marwan Saad
Journal:  Ann Med       Date:  2020-05-22       Impact factor: 4.709

Review 5.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

6.  Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Alexandra Katsimardou; Maria Toumpourleka; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-15       Impact factor: 3.738

7.  Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Arterial Stiffness and Aabnormal Left Ventricular Hemodynamic Responses During Exercise.

Authors:  Emily K Zern; Jennifer E Ho; Lindsay G Panah; Emily S Lau; Elizabeth Liu; Robyn Farrell; John A Sbarbaro; Mark W Schoenike; Paul P Pappagianopoulos; Mayooran Namasivayam; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis
Journal:  J Card Fail       Date:  2021-02-26       Impact factor: 6.592

Review 8.  Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Konstantinos Stavropoulos; Ioanna Zografou; Michael Doumas; Asterios Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-14       Impact factor: 3.738

Review 9.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 10.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.